GYNECOLOGIC CANCERS

The expanded version of the BD Onclarity HPV Assay received approval for a pre-market approval supplement from the FDA, making it the only assay approved right now that individually identifies and reports human papillomavirus genotypes 31, 51, 52, 33/58, 35/39/68, and 56/59/66, as well as the standard 16,18, and 45.

A pathogenic germline mutation rate of about 5% has been identified in women who had a family history of breast or ovarian cancer but no personal history of either disease.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

The first randomized study of an ATR inhibitor in any malignancy demonstrated the benefit of berzosertib added to gemcitabine as treatment of patients with platinum-resistant high-grade serous ovarian cancer, according to a recently published study.

In an interview with Targeted Oncology, Joyce F. Liu, MD, MPH, discussed the details of the phase 2 study of adavosertib in recurrent uterine serous carcinoma and the implications of this research for clinical practices.

According to investigators on the phase 2 I-SPY 2 study, the addition durvalumab plus olaparib to treatment with neoadjuvant paclitaxel led to better pathologic complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer compared with paclitaxel alone.

Leslie M. Randall, MD, MAS, discussed the treatment regimens available for an African American patient with ovarian cancer.

Bradley Monk, MD, discusses the phase 1b/2 innovaTV 205 trial in patients with recurrent or metastatic cervical cancer.

The addition of trastuzumab to chemotherapy in patients with uterine serous carcinoma had superior outcome compared with chemotherapy alone.

"Available therapies upon progression after first-line chemotherapy in recurrent or metastatic cervical cancer are limited, and there is a significant unmet need for new treatment options."

With multiple treatment options available in the ovarian cancer landscape, experts are now looking for an answer to the challenging question of optimal sequencing.

“Cervical cancer screening rates are suboptimal among Asian American women, despite considerable efforts to improve Pap test screening."

“We are starting to see more and more patients with recurrent ovarian cancer, we’re treating them much more aggressively in the up-front setting, and we have to face PARP inhibitor resistance in the future.”

Mansoor R. Mirza, MD, discusses the results of the PRIMA study of niraparib in patients with advanced ovarian cancer and the evaluation of the starting dose in these patients.

In the treatment landscape for advanced cervical cancer, no approved options exist for patients after first-line treatment. Based on phase 2 data, camrelizumab plus apatinib is showing promise.

Anlotinib appeared safe with a manageable toxicity profile as treatment of patients with recurrent advanced cervical cancer in a phase 2 study.

Mansoor Raza Mirza, MD, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib plus bevacizumab versus niraparib alone in recurrent platinum-sensitive ovarian cancer.

Statistically significant improvements in time to second progression or death, or PFS2, was demonstrated in the bevacizumab/niraparib combination, as well as other positive clinical outcomes.

"In this trial, [mirvetuximab soravtansine] was combined with bevacizumab for a broader segment of recurrent ovarian cancer patients, regardless of platinum status."

Despite missing the primary end point of progression-free survival improvement, cediranib and olaparib demonstrated comparable activity with platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian cancer.

Brian M. Slomovitz, MD, discusses the some of the subcategories of endometrial cancer and how the make a difference for patients’ treatment.

"It is a proof of concept of the efficacy of an immunotherapy in [patients with] gestational trophoblastic tumors , confirming the rationale we had."

Bradley J. Monk, MD, FACS, FACOG, discusses the remaining challenges in conducting clinical trials for patients with cervical cancer.

Encouraging survival outcomes were seen with trametinib in patients with low-grade serous ovarian cancer treated in a phase II/III clinical trial.

In an interview with Targeted Oncology, Robert L. Coleman, MD, FACOG, FACS, discussed the importance of molecular testing in ovarian cancer and how the treatment landscape will continue to evolve in tailoring treatment to patients based on the biology of their tumors, which was the topic of his lecture at the 2020 Society for Gynecologic Oncology (SGO) Annual Meeting.